
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna is a rapidly growing biotech company with a promising pipeline of mRNA-based therapies in various therapeutic areas. Their pioneering mRNA technology, validated by the success of their COVID-19 vaccine, positions the company for long-term success. With a solid balance sheet, a diverse and innovative pipeline, and successful clinical trial data, Moderna is well-positioned for future growth and potential partnerships.
Bears say
Moderna is at a high-risk for stock price volatility and future revenue instability due to the uncertainty of the success of their varied and wide-ranging pipeline, recent discontinuations of certain programs, and the possibility of future program failures. Additionally, the current market cap of $24.64 billion is significantly higher than the projected YE:26E cash of $3.71 billion, which leads to concerns about financial stability and the use of the Ares credit facility. Further, the potential setbacks in trials for the COVID-19 vaccine, as well as the unproven efficacy of cancer vaccines, are cause for caution and leads to a negative outlook for Moderna.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares